Notably, liposomal IL-2 was most effective in intraperitoneal tumor models, with the combination therapy showing no significant toxicity, reinforcing the potential of liposomal chemoimmunotherapy for treating metastatic and regionally spread tumors [159]. Here, IL2 is linked to neoplasm.